Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-labeled monoclonal antibody 250-30.6
- Development stage
- Unknown
- Lead developer
- University of Melbourne
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
131I-labeled monoclonal antibody 250-30.6 is a radiopharmaceutical consisting of a murine monoclonal antibody, 250-30.6, conjugated to the radioactive isotope Iodine-131. The antibody specifically targets a cell-surface antigen associated with human colorectal carcinoma. Primarily utilized for immunoscintigraphy, this agent allows for the non-invasive detection and localization of primary and metastatic colon cancer deposits via gamma camera imaging. Clinical evaluations have demonstrated high sensitivity in detecting metastatic lesions in the liver and other sites, though its reactivity can extend to other adenocarcinomas such as those of the pancreas and breast.
- Other names
- 131I-250-30.6Iodine-131 monoclonal antibody 250-30.6Iodine131 monoclonal antibody 250-30.6Iodine 131 monoclonal antibody 250-30.6131I-labeled mAb 250-30.6
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on 131I-labeled monoclonal antibody 250-30.6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-labeled monoclonal antibody 250-30.6.